Early outcomes of minimally invasive surgery versus thoracotomy for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a multi-center propensity score- matched study

Author:

Pan Hanbo1,Chen Hang2,Ge Zhen3,Ning Junwei4,Kong Weicheng5,Tian Yu1,Zou Ningyuan1,Zhu Hongda1,Zhang Jiaqi1,Tao Yixing1,Gu Zenan1,Jiang Long1,Zheng Min4,Zhou Chengwei3,Ruan Guomo6,Li Ziming1,Hu Yingjie1,Huang Jia1,Xu Guodong2,Luo Qingquan1

Affiliation:

1. Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine

2. The Affiliated Lihuili Hospital of Ningbo University

3. The First Affiliated Hospital of Ningbo University

4. Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine

5. Zhoushan Putuo District People’s Hospital

6. Shanghai University School of Medicine

Abstract

Abstract Background Neoadjuvant immunochemotherapy has revolutionized the treatment of non-small lung cancer (NSCLC) but may notably escalate the surgery’s intricacy. Consequently, the sufficiency of minimally invasive surgery (MIS) remains controversial. This study aims to assess the safety and feasibility of MIS for NSCLC patients after induction immunochemotherapy. Methods NSCLC patients with neoadjuvant immunochemotherapy who underwent MIS or open lobectomy at six institutions from 2019 to 2023 were retrospectively identified. Propensity-score matching (PSM) was applied to balance baseline clinical characteristics. Results A total of 186 cases were included, and PSM led to 84 patients in MIS and OPEN groups. The baseline clinical characteristics and induction-related adverse events were comparable between the two groups (all P > 0.050). 11.9% of MIS converted to thoracotomy. By comparison, the MIS group was associated with reduced blood loss (100 [100–125] vs. 100 [100–200] mL, P = 0.011), shortened chest tube duration (5 [4–7] vs. 6 [5–8] days, P = 0.007), and decreased assessed lymph nodes (LNs; 12 [9–15] vs. 14 [11–20], P = 0.007) compared with the OPEN group. The two groups had no difference in the other surgical and pathological outcomes (all P > 0.050). Finally, MIS reduced postoperative complications compared with thoracotomy (23.8% vs. 39.3%, P = 0.031) Conclusion MIS is safe and feasible for NSCLC patients with neoadjuvant immunochemotherapy, with the advantages of lower blood loss, faster recoveries, and fewer postoperative complications and the disadvantage of LN assessment compared with thoracotomy.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3